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This study intended to quantify the impact of AIDS-defin-
ing cancers on the risk of death in the post-HAART era.
With this aim in mind, data regarding all Italian AIDS
cases reported to the National AIDS Registry were ana-
lyzed.
Between 1999 and 2005, a total of 12,433 individuals
were diagnosed with AIDS in Italy. Specifically excluded
from this analysis were people with AIDS who were: 1)
not-Italian citizen (n = 1918); 2) resident in Italian areas
where individual information on death was not available
(n = 108); 3) resident in unknown areas (n = 119); 4)
pediatric or vertical transmission cases (n = 50); 5) diag-
nosed solely at autopsy (n = 576). The presence of AIDS-
defining cancers (i.e., Kaposi's sarcoma-KS, non-Hodgkin
lymphoma-NHL, and invasive cervical cancer-ICC) at
AIDS diagnosis is routinely ascertained at the National
AIDS Registry, together with some other information,
including age, sex, date of AIDS diagnosis, HIV transmis-
sion category, CD4+ cells count. Information on vital sta-
tus of AIDS cases, as of December 2006, was assessed
through a semi-automated linkage procedure, ensuring
confidentiality of individual data, with the national death
certificates database. Survival function was estimated by
the Kaplan-Meier method; Cox regression model was used
to estimate death hazard ratios (HR), and corresponding
95% confidence intervals (CI), associated to the presence
of AIDS-defining cancers at diagnosis, adjusted for age at
AIDS diagnosis, sex, HIV transmission category, and
CD4+ cells count at diagnosis.
Of the 9,662 AIDS cases included in the present study,
478 had KS, 429 immunoblastic NHL, 158 Burkitt's lym-
phoma, 69 ICC, and 58 NHL of the central nervous sys-
tem (CNS). As of December 2006, 3,096 deaths were
registered: of these deaths, 505 occurred among cases with
AIDS-defining cancers. The proportion of AIDS cases still
alive 5 years after AIDS diagnosis was 66.6 percent. The
shortest survival period was seen among individuals diag-
nosed with CNS NHL (median survival = 4 months), fol-
lowed by those with immunoblastic NHL or Burkitt's
lymphoma (median survival = 16 and 38 months, respec-
tively), whereas the longest ones were recorded among
cases with ICC or KS (median not reached). In compari-
son with AIDS cases without AIDS-defining cancers, those
with a CNS NHL had a 4.7-fold higher risk of death (95%
CI: 3.5–6.4), those with immunoblastic NHL or Burkitt's
lymphoma had more than twice the risk (HR = 2.6, 95%
CI: 2.2–2.9; and HR = 2.3, 95% CI: 1.8–2.8, respectively),
and, among women, those with ICC had a 1.8-fold ele-
vated risk (95% CI: 1.2–2.7). Conversely, among individ-
uals with KS (HR = 0.7, 95% CI: 0.6–0.9) the risk of death
was lower than that of cases without AIDS-defining can-
cers.
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In conclusion, this exhaustive survival analysis of Italian
AIDS cases in the post-HAART era highlighted the persist-
ing lethality of NHL and the long survival of cases with KS
and ICC.Page 2 of 2
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